Original Source(s)
Related Content
Can LAI-CAB Sustain Long-Term PrEP Use?
A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.
July 17, 2026
-
4 min
FDA Approves First Oral PCSK9 Inhibitor
Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.
July 16, 2026
-
2 min
